Chromos and Xencor announce agreement for use of the ACE System to produce biologics. Burnaby, British Columbia, Canada and Monrovia, California, United States – Chromos Molecular Systems Inc. (“Chromos“ TSX: CHR) and Xencor announced today that they have entered into a non-exclusive research
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 2, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane Leone , CFA, has joined Xencor as senior vice
Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Monrovia, Calif. January 19, 2010 A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies
Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells Monrovia, CA – March 7, 2006 – Engineering the “Fc“ region of monoclonal antibodies (mAbs) increases their toxicity to cancer cells, potentially improving the utility of targeted cancer
Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier (BW Healthwire)–June 04, 2002—Xencor’s Vice President, Discovery Technologies, Robert Pacifici, Ph.D., Presents at BIO 2002, June 10 at 10:30 a.m.-12:00 p.m. in room 701A. Monrovia, CA – Xencor, a drug discovery company
FierceBiotech Honors Xencor as One of the MONROVIA, CA – June 21, 2005 – Xencor, Inc., a company engineering superior biotherapeutics using its Protein Design Automation® technology, announced today that it has been selected as one of the “Fierce 15“ for 2005 by FierceBiotech, an internationally
Human Genome Sciences And Xencor Announce Antibody Collaboration ROCKVILLE, Maryland and MONROVIA, California – February 7, 2008 – Human Genome Sciences, Inc. (Nasdaq: HGSI) and Xencor, Inc. today announced a collaboration agreement under which Xencor will apply its proprietary XmAb™ humanization
MONROVIA, Calif. , Feb. 18, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that investigators John H.
Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced the appointment of Jeffrey D. Bloss, M.D., F.A.C.O.G., as chief medical officer. Dr.
